

[Enalapril](#)

Essential medicine status

Section:

[12. Cardiovascular medicines](#) [12.3. Antihypertensive medicines](#)

ATC codes: [C09AA02](#)

EMLc

Indication

Essential hypertension ICD11 code: [BA00.Z](#)

INN

Enalapril

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Liquid: 1 mg per mL (as hydrogen maleate) (EMLc)

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate) ; 5 mg (as hydrogen maleate) ; 10 mg (as hydrogen maleate)

EML status history

First added in 2003 ([TRS 920](#))

Changed in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: C09AA ACE inhibitors, plain.

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: C09AA ACE inhibitors, plain.

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Enalapril](#)

DrugBank

[Enalapril](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of enalapril 10 mg tablets to the EML and EMLc and the addition of enalapril 1 mg/mL oral liquid to the EMLc.